Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
Steven M. Opal(Brown University), Michael G. Seneff(Apple (Israel)), Jerald Sadoff(University of Maryland, Baltimore), Robert P. Baughman(University of Cincinnati), Eric J. DeMaria(Virginia Commonwealth University Medical Center), Rainer Brase(Apple (Israel)), Gus J. Slotman(Apple (Israel)), Howard Levy(Apple (Israel)), John P. Pribble(Apple (Israel)), Jean-François Dhainaut(Apple (Israel)), Charles J. Fisher, R.A. Balk(Apple (Israel)), James E. Norman(National Institutes of Health), Klaus E. Matzel(Friedrich-Alexander-Universität Erlangen-Nürnberg), Edward Abraham(New York Medical College), John F. LaBrecque(Apple (Israel)), Janice L. Lookabaugh(Apple (Israel)), Howard G. Dubin(Apple (Israel)), Stephen F. Lowry, Jean‐Louis Vincent(Université Libre de Bruxelles), M. P. Shelly(Apple (Israel)), H. C. E. Donovan(Apple (Israel))
Cited by 863
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.7k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k